EDUCATION

M.D. (equivalent), Second Military Medical University, China, July 30, 1979

Ph.D., Pharmacology, Université Claude Bernard Lyon 1, France, October 23, 1986
Thesis: Activite cardiovasculaire et baroreflex chez le rat genetiquement hypertendu de souche Lyonnaise, Page 1–175.
Ph.D. student period: September, 1982 - October, 1986
Mentor: Jean Sassard, M.D., Ph.D., Professor of Pharmacology and Physiology.

Training: French Language training
Shanghai Foreign Language University, February – July, 1982.
Université Bordeaux I, July – August 1982.

PROFESSIONAL POSITIONS

Assistant, Department of Pharmacology, Second Military Medical University, Shanghai, China, May, 1980 – July, 1982

Maitre de Conference Invité, Faculte de Pharmacie, Université Claude Bernard, Lyon, France, October, 1986 – September, 1987

Vice Professor, Department of Pharmacology, Second Military Medical University, Shanghai, China, September, 1987 – January, 1989

Vice-Director, Department of Pharmacology, Second Military Medical University, Shanghai, China, October, 1988 – December, 1991

Professor, Department of Pharmacology, Second Military Medical University, Shanghai, China, February, 1989 – Present

Director, Department of Pharmacology, Second Military Medical University, Shanghai, China, January, 1992 – Present 

Professeur Invité, Faculte de Pharmacie, Université Claude Bernard, Lyon, France, June-July, 2001

PROFESSIONAL SOCIETIES

Chinese Pharmacological Society, Vice-President (Since 2002)

Shanghai Pharmacological Society, President (2000 - 2005)

Shanghai Pharmacological Society, Honorary President (Since 2005)

Chinese Society of Cardiovascular Pharmacology, President (2000 - 2004)

Chinese Society of Cardiovascular Pharmacology, Honorary President (Since 2004)

American Heart association (AHA), Fellow, Council on High Blood Pressure Research (Since 2003)

The Asian Society for vascular Biology, Executive Committee Member (Since 2004)

The IUPHAR Integrative and Organ Systems Pharmacology (IOSP) Committee, Member (Since 2008)

World Hypertension League & China Hypertension League, Member (since 1993)

Chinese Section, International Society for Heart Research, Member (since 1998)

Chinese Physiological Society, Member (since 2001)

Ethic Committee of Second Military Medical University, President (Since 2006)

SERVICES FOR JOURNALS
 
Editor-in-Chief:

Clinical and Experimental Pharmacology and Physiology (CEPP, Editor-in-Chief, Since 2007.1)

Frontier in Pharmacology of Natural Products (FPNP, Editor-in-Chief, Since 2010.3)

Acta Pharmacologica Sinica (APS, Vice Editor-in-Chief, Since 2003.1)

Frontier in Pharmacology (Associate Editor, since 2010.3)

Family Medicine (in Chinese, EiC 2001.1-2008.9; Honorary EiC Since 2008.9)

Academic Journal of Second Military Medical University (in Chinese, Vice EiC, Since 2006.4)

Editorial Board Member (International Journals):

Acta Pharmacologuca Sinica (Since 1990.1)

Journal of Cardiovascular Pharmacology (1993.2-1998.8；2004.8-Present)

Clinical and Experimental Pharmacology and Physiology (Since 1994.4)

Clinical Science (Adviser, Since 2006.5)

Editorial Board Member (Chinese Journals):

Academic Journal of Second Military Medical University (Since 1990.1)

Chinese Journal of Hypertension (Since 1995.5)

Chinese Pharmacological Bulletin (Since 1998.4)

Chinese Journal of Clinical Pharmacology and Therapeutics (Since 2003.1)

World Clinical Drugs (Since 2005.9)

Asian Journal of Pharmacodynamics & Pharmacokinetics (Since 2006.4)

Pharmaceutical Care and Research (Since 2006.1)

Journal of Internal Medicine – Concepts & Practice (Since 2006.7)

China Licensed Pharmacist (Since 2008.11)

Acta Pharmaceutica Sinica (Since 2008.11) 

HONORS AND IMPORTANT AWARDS

Su DF, Miao CY, Shen FM, Xie HH, Liu JG. Studies on blood pressure and organ damages. National Award for Natural Science (Second Class), Chinese Government, Augest, 2009. (The first class of this award is often vacant)

Su DF, Miao CY, Shen FM, Xie HH, Liu JG. Baroreflex and cardiovascular diseases. Award for Natural Science (Second Class), Shanghai Municipal Government, December, 2006

Su DF, Miao CY, Tao X, Shen FM, Shan ZZ. Study of blood pressure variability. Award for Science and Technology Development (First Class), Shanghai Municipal Government, December 28, 2003

Su DF, Cheng Y, Kong XB, Zhang H, Yang YC, Chen L, Yang J. Arterial baroreflex and its interaction with ketanserin. Army Award for Science and Technology Development (Second Class), General Logistics Department of the People’s Liberation Army, October 5, 1992

Miao CY. Cardiovascular hypertrophy and its mechanisms in sinoaortic-denervated rats. Second Military Medical University. Doctoral thesis, Page 1-142, June, 2000. (Su DF as the Mentor) National Excellent Doctoral Thesis, Ministry of Education of the People’s Republic of China, August, 2003

PATENTS (totally 16 patents)

National Invention Patent, Patent number: ZL 02 1 12049.8, National Knowledge Property Administration of the People’s Republic of China, July 21, 2004
(Su DF, Cai GJ, Shen FM, Miao CY. Scopolamine compound. Application date: June 13, 2002)

National Invention Patent, Patent number: ZL 02 1 10894.3, National Knowledge Property Administration of the People’s Republic of China, September 29, 2004
(Su DF, Miao CY. A method for breeding the spontaneously arterial baroreflex-deficient rats. Application date: February 26, 2002)

National Invention Patent, Patent number: ZL 02 803331.0, National Knowledge Property Administration of the People’s Republic of China, May 8, 2002
(Wang JH, Su DF. An anti-cardial reperfusion injury drug. Application date: February 8, 2006)

National Invention Patent, Patent number: ZL 200610116322.8, National Knowledge Property Administration of the People’s Republic of China, September 21, 2006
(Su DF, Yu XH, Liu AJ, Cai GJ. A new compound medasuping and its purpose. Application date: September 3, 2008)

NEW DRUGS

Nitrenlol tablet, a new drug was approved for clinical study of hypertension treatment. Official document number: 2002HL0629, State Food and Drug Administration (SFDA) of the People’s Republic of China, October 14, 2002. It was approved for marketing by SFDA on January 17, 2009.

RESEARCH GRANTS

Active
Scientist-in-Chief, Project of the Major State Basic Research Development Program of the People’s Republic of China (973 Program), 2009CB521900, “Basic research of the occurrence, prevention and treatment of cerebral vascular diseases” RMB30,000,000, January, 2008- December, 20012.

Principal investigator, National Applied Research Program of China (863 Program), №2006AA02Z4C1 ““New strategies for the prevention of stroke”,  RMB2,600,000, January, 2007-December, 2008.

Principal investigator, National Natural Science Foundation of China, №30670833, “Effects and mechanisms of calorie restriction on stroke in SHR-SP” RMB300,000, January, 2007-December, 2009

Principal investigator, Shanghai Foundation for Science and Technology Development, №07JC14065, “The study of arterial baroreflex (ABR) dysfunction as an important mechanisms in the regulation of stroke”, RMB200,000, December, 2007-November 2009.

Principal investigator, National Natural Science Foundation of China (key project), №30730106, “Basic research of the stroke prevention”, RMB1,500,000, January, 2008-December, 2010.

Past
Principal investigator, National Natural Science Foundation of China, №3880743, “Arterial baroreflex and the antihypertensive mechanism of ketanserin.”, RMB25,000, January, 1989-December, 1990

Principal investigator, Foundation of the General Logistics Department of People’s Liberation Army, “Antihypertensive effects of Chinese medicine.”, RMB60,000, January, 1989-December, 1993

Principal investigator, The Foundation of Education Minister for Excellent Young Teachers, “The mechanisms of blood pressure variability.”, RMB52,800, January, 1989-December, 1991

Principal investigator, National Natural Science Foundation of China, №39070934, “The effects and the mechanisms of ketanserin on blood pressure variability.” RMB25,000, January, 1991-December, 1992

Principal investigator, National Natural Science Foundation of China, №39170346, “Blood pressure variability and hypertension.”, RMB35,000, January, 1992-December, 1993

Principal investigator, National Natural Science Foundation of China, №39670831, “Instability of blood pressure-induced organ damages and the drug interference.”, RMB90,000, January, 1997-December, 1998

Principal investigator, National Natural Science Foundation of China, №30070871, “The mechanisms underlying instability of blood pressure-induced organ damages in rats.”, RMB130,000, January, 2001-December, 2003

Co-principal investigator (with Dr. Miao CY), Shanghai Foundation for Science and Technology Development, №014909004, “The development of a rat strain: spontaneously arterial baroreflex-deficient rat (ABR-DR).”, RMB300,000, October, 2001-September, 2004

Principal investigator, National Natural Science Foundation of China, №30170385 “Arterial baroreflex dysfunction in rats.”, RMB200,000, January, 2002-December, 2004

Principal investigator, Shanghai Foundation for Science and Technology Development, №03JC14001, “the contribution of arterial baroreflex (ABR) dysfunction to Cardiovascular diseases.” RMB300,000, October, 2003- September, 2006

Principal investigator, National Natural Science Foundation of China (key project), №30330650 “Restoration of arterial baroreflex function as a new strategy for treating cardiovascular diseases.”, RMB1,500,000, January, 2004-December, 2007

Principal investigator, Shanghai Foundation for Science and Technology Development, №044319219, “the pharmacy and pharmacodynamics of a new anti-MS drug SMMU 9601.”, RMB400,000 October, 2004- July, 2007

BIBLIOGRAPHY (14 books, 112 articles published in international journals)

Books, Su DF as editor, are listed, and others, SU DF as author, are omitted.

1. “Progress in Cardiovascular Pharmacology”, Eds. Chen WZ, Chen X, Han QD and Su DF. People’s Health Press, Beijing, Page 1-290, 1995.

2.  “Progress in Pharmacology (1997)”, Eds. Jin ZY, Wang YM and Su DF. People’s Health Press, Beijing, Page 1-243, 1997.

3.  “Progress in Pharmacology (1998)”, Eds. Jin ZY, Wang YM and Su DF. Science Press, Beijing, Page 1-277, 1998.

4.  “Progress in Pharmacology (1999)”, Eds. Jin ZY, Wang YM and Su DF. Science Press, Beijing, Page 1-287, 1999.

5.  “Progress in Pharmacology (2000)”, Eds. Wang YM and Su DF. Science Press, Beijing, Page 1-227, 2000.

6.  “Cardiovascular Pharmacology”, Eds. Su DF, and Miao CY. Science Press, Beijing, Page 1-455, 2001

7.  “Progress in Pharmacology (2001)”, Eds. Su DF, Miao CY, and Wang YM. People’s Health Press, Beijing, Page 1-309, 2002

8.  “Progress in Pharmacology (2002)”, Eds. Su DF, Miao CY, and Wang YM. People’s Health Press, Beijing, Page 1-212, 2002

9.  “Progress in Pharmacology (2003)”, Eds. Su DF, Miao CY, and Wang YM. People’s Health Press, Beijing, Page 1-345, 2003

10.  “Pharmacology” (For Clinical Medicine Students, Edition 6), Eds. Yang BF, Su DF. People’s Health Press, Beijing, Page 1-526, 2003.

11.  Chinese Edition of “The pharmacological basis of therapeutics”(edition 10) Eds. Jin YY, Chen RZ, Du GH, Li WH, Lin ZB, Qiu PL, Su DF, Wang YS, Xu SY and Yin M, People’s Health Press, Beijing, Page 1-1643, 2004.

12.  “Progress in Pharmacology (2004)”, Eds. Su DF, Miao CY, and Wang YM. People’s Health Press, Beijing, Page 1-318, 2004

13.  “Progress in Pharmacology (2005)”, Eds. Su DF, Miao CY, and Wang YM. People’s Health Press, Beijing, Page 1-301, 2005

14.  “Pharmacology” (For Clinical Medicine Students, Edition 7), Eds. Yang BF, Su DF. People’s Health Press, Beijing, 2008.

15.  “Cardiovascular Pharmacology”(Second Edition), Eds. Su DF, and Miao CY. Science Press, Beijing, 2010.

16.  “Blood pressure and the measurement of blood pressure”, Eds. Zhu DL, Zhang WZ, Wang JG, Su DF. People’s Military Medicine Press, Beijing, 2010.

17.  “Progress in Pharmacology (2006-2010)”, Eds. Su DF, Miao CY, and Shen FM. People’s Health Press, Beijing, 2011.

18.  “Cardiovascular Pharmacology”(Fourth Edition), Eds. Su DF, Chen FY and Miao CY. People’s Health Press, Beijing, 2011.

Full articles published in SCI-cited journals (excluding abstracts and articles published in Chinese journals)

1984-1990

1.  Cerutti C, Su DF, Barres C, Paultre CZ, Sassard J. Computerized analysis of cardiovascular activity in the conscious unrestrained rat. Application to the study of a new antihypertensive agent. Arch Mal Coeur Vaiss 1984; 77(11): 1167-71.

2.  Su DF, Cerutti C, Barres C, Paultre CZ, Vincent M, Sassard J. Computer analysis of cardiovascular activity in conscious unrestrained hypertensive rats of the Lyon strain. Clin Exp Hypertens A 1985; 7(2-3): 413-6.

3.  Su DF, Cerutti C, Barres C, Paultre C, Vincent M, Sassard J. Computerized study of cardiovascular activity and baroreflex sensitivity in conscious unrestrained genetically hypertensive rats of the Lyon strains. J Hypertens 1986; 4(Suppl 3): S233-4.

4.  Su DF, Cerutti C, Barres C, Vincent M, Sassard J. Blood pressure and baroreflex sensitivity in conscious hypertensive rats of Lyon strain. Am J Physiol 1986; 251(6 Pt 2): H1111-7.

5.  Su DF, Julien C, Kandza P, Sassard J. Circadian changes in the sensitivity of the baroreflex in the conscious rat. C R Acad Sci III 1987; 305(19): 683-6.

6.  Su DF, Barres C, Lo M, Cerutti C, Vincent M, Sassard J. Sensitivity of the cardiac baroreflex in genetically hypertensive rats of a Lyons strain. Arch Mal Coeur Vaiss 1987; 80(6): 924-8.

7.  Julien C, Cerutti C, Kandza P, Barres C, Su DF, Vincent M, Sassard J. Cardiovascular response to emotional stress and spontaneous blood pressure variability in genetically hypertensive rats of the Lyon strain. Clin Exp Pharmacol Physiol 1988; 15: 533-8.

8.  Lo M, Su DF, Julien C, Cerutti C, Vincent M, Sassard J. Influence of hypertension and age on the sympathetic and parasympathetic components of cardiac baroreflex in the conscious rat. Arch Mal Coeur Vaiss 1988; 81 Spec No: 113-7.

9.  Lo M, Cerutti C, Julien C, Su DF, Vincent M, Sassard J. Evolution with age of baroreflex sensitivity and its autonomic nervous components in conscious hypertensive rats of the Lyon strain. Clin Exp Pharmacol Physiol Suppl 1989; 15: 81-4.

1991-1995

10.  Miao CY, Zhang FL, Zhu QY, Zhang KH, Su DF. Effects of tetrandrine on hypertensive responses induced by electric stimulation and a-adrenoceptor agonists in pithed rats. Acta Pharmacol Sin 1991; 12(4): 352-4.

11.  Yang J, Bao J, Su DF. Effects of serotonin and norepinephrine on neuronal discharges of the nucleus tractus solitarii in medullary slices. Acta Pharmacol Sin 1992; 13(1): 42-4.

12.  Chen H, Su DF, Zhang TH, Ding HJ, Yang YC, Chen SC. Effects of silybin on acute myocardial infarction and reperfusion injury in anesthetized rats. Acta Pharmacol Sin 1992; 13(1): 69-71.

13.  Julien C, Sacquet J, Kandza P, Su DF, Vincent M, Barres C. Cardiovascular habituation to emotional stress in Lyon hypertensive rats. Clin Exp Pharmacol Physiol 1992; 19(3): 187-92.

14.  Su DF, Yang YC, Xie JE. Effects of ketanserin on blood pressure and heart rate in sinoaortic denervated rats. Eur J Pharmacol 1992; 214(1): 89-91.

15.  Cheng Y, Kong XB, Su DF. Effects of ketanserin on blood pressure variability in conscious spontaneously hypertensive rats. Acta Pharmacol Sin 1992; 13(3): 235-8.

16.  Zhu QY, Jin G, Yan ZL, Miao CY, Su DF. Inhibitory effects of neferine and tetrandrine on portal vein and papillary muscle in rats. Acta Pharmacol Sin 1992; 13(4): 359-61.

17.  Miao CY, Zhu QY, Yang YC, Su DF. Antihypertensive effects of atenolol and nitrendipine alone or in combination on three hypertensive models of rats. Acta Pharmacol Sin1992; 13(5): 448-51.

18.  Kong XB, Cheng Y, Su DF. Effect of ketanserin on arterial baroreflex-blood pressure control in conscious hypertensive rats. Acta Pharmacol Sin 1992; 13(6): 517-20.

19.  Su DF, Cerutti C, Barres C, Julien C, Vincent M, Paultre C, Sassard J. Arterial baroreflex control of heart period is not related to blood pressure variability in conscious hypertensive and normotensive rats. Clin Exp Pharmacol Physiol 1992; 19(11): 767-76.

20.  Chen H, Chen SC, Zhang TH, Tian HC, Guan Y, Su DF. Protective effects of silybin and tetrandrine on the outcome of spontaneously hypertensive rats subjected to acute coronary artery occlusion. Int J Cardiol 1993; 41(2): 103-8.

1996-2000

21.  Dai SM, Shan ZZ, Miao CY, Yin M, Su DF. Hemodynamic responses to endothelin-1 and endothelin antagonists microinjected into the nucleus tractus solitarius in rats. J Cardiovasc Pharmacol 1997; 30(4): 475-80.

22.  Shan ZZ, Dai SM, Su DF. Relationship between baroreceptor reflex function and end-organ damage in spontaneously hypertensive rats. Am J Physiol 1999; 277(3 Pt 2): H1200-6.

23.  Shen FM, Su DF. The effect of adenosine on blood pressure variability in sinoaortic denervated rats is mediated by adenosine A2a-Receptor. J Cardiovasc Pharmacol 2000; 36(5): 681-6.

2001

24.  Miao CY, Tao X, Gong K, Zhang SH, Chu ZX, Su DF. Arterial remodeling in chronic sinoaortic-denervated rats. J Cardiovasc Pharmacol 2001; 37(1): 6-15.

25.  Miao CY, Shen FM, Su DF. Blood pressure variability is increased in genetic hypertension and L-NAME -induced hypertension. Acta Pharmacol Sin 2001; 22(2): 137-40.

26.  Shan ZZ, Dai SM, Su DF. Arterial baroreflex deficit induced organ damage in sinoaortic denervated rats. J Cardiovasc Pharmacol 2001; 38(3): 427-37.

27.  Guan Y, Miao CY, Su DF. Effects of six antihypertensive drugs on blood pressure and hypothalamic GABA content in spontaneously hypertensive rats. Fundam Clin Pharmacol 2001; 15(4): 221-6.

28.  Su DF, Miao CY. Blood pressure variability and organ damage. Clin Exp Pharmacol Physiol 2001; 28(9): 709-15.

29.  Chen H, Higashino H, Maeda K, Zhang Z, Ohta Y, Wang Z, Su DF, Yuan WJ. Reduction of cardiac norepinephrine improves postischemic heart function in stroke-prone spontaneously hypertensive rats. J Cardiovasc Pharmacol 2001; 38(6): 821-32.

2002

30.  Su DF, Chen L, Kong XB, Cheng Y. Determination of arterial baroreflex-blood pressure control in conscious rats. Acta Pharmacol Sin 2002; 23(2): 103-9.

31.  Su DF, Miao CY. Arterial baroreflex function in conscious rats. Acta Pharmacol Sin 2002; 23(8): 673-9.

32.  Miao CY, Xie HH, Wang JJ, Su DF. Candesartan inhibits sinoaortic denervation-induced cardiovascular hypertrophy in rats. Acta Pharmacol Sin 2002; 23(8): 713-20.

33.  Miao CY, Su DF. The importance of blood pressure variability in rat aortic and left ventricular hypertrophy produced by sinoaortic denervation. J Hypertens 2002; 20(9): 1865-72.

34.  Xie HH, Miao CY, Liu JG, Su DF. Importance of blood pressure variability in organ protection in spontaneously hypertensive rats treated with combination of nitrendipine and atenolol. Acta Pharmacol Sin 2002; 23(12): 1199-204.

2003

35.  Wang WZ, Yuan WJ, Yang J, Wang JW, Tang CS, Su DF. Involvement of I(1)-imidazoline receptors in baroreceptor reflex in the caudal ventrolateral medulla of rats. Brain Res 2003; 960(1-2): 16-24.

36.  Miao CY, Su DF. Arterial baroreflex function and left ventricular hypertrophy. Drug Develop Res 2003; 58(1): 61-4.

37.  Lu ZA, Xie HH, Xu LP, Yin AF, Miao CY, Su DF. Restoration of arterial baroreflex function contributes to organ protection in spontaneously hypertensive rats treated with long-term hydrochlorothiazide mixture. Clin Exp Pharmacol Physiol 2003; 30(1-2): 49-54.

38.  Du WM, Miao CY, Liu JG, Shen FM, Yang XQ, Su DF. Effects of long-term treatment with ketanserin on blood pressure variability and end-organ damage in spontaneously hypertensive rats. J Cardiovasc Pharmacol 2003; 41(2): 233-9.

39.  Xie HH, Miao CY, Liu JG, Su DF. Effects of long-term treatment with candesartan on organ damages in sinoaortic denervated rats. J Cardiovasc Pharmacol 2003; 41(2): 325-31.

40.  Miao CY, Xie HH, Yu H, Chu ZX, Su DF. Ketanserin stabilizes blood pressure in conscious spontaneously hypertensive rats. Clin Exp Pharmacol Physiol 2003; 30(3): 189-93.

41.  Tao X, Zhang SH, Chu ZX, Su DF. Apoptosis is involved in the cardiac damage induced by sinoaortic denervation in rats. Clin Exp Pharmacol Physiol 2003; 30(5-6): 362-8.

42.  Wang WZ, Yuan WJ, Ren AJ, Pan YX, Tang CS, Su DF. Role of I1-imidazoline receptors within the caudal ventrolateral medulla in cardiovascular responses to clonidine in rats. J Cardiovasc Pharmacol 2003; 42(1): 1-9.

43.  Miao CY, Yuan WJ, Su DF. Comparative study of sinoaortic denervated rats and spontaneously hypertensive rats. Am J Hypertens 2003; 16(7): 585-91.

44.  He CX, Miao CY, Yao JH, Chen HM, Lu DR, Su DF, Xue JL. Construction of a recombinant vector based on AAV carrying human endothelial nitric-oxide synthase gene. Acta Pharmacol Sin 2003; 24(7): 637-40.

45.  Miao CY, Zhang LM, Yuan WJ, Su DF. Angiotensin II and AT1 receptor in hypertrophied ventricles and aortas of sinoaortic-denervated rats. Acta Pharmacol Sin 2003; 24(8): 812-8.

46.  Liu JG, Shu H, Shen FM, Miao CY, Su DF. Effects of glucose-insulin-potassium on baroreflex sensitivity, left ventricular function and ventricular arrhythmia in the subacute phase of myocardial infarction in rats. Fundam Clin Pharmacol 2003; 17(4): 443-8.

47.  Liu JG, Xu LP, Chu ZX, Miao CY, Su DF. Contribution of blood pressure variability to the effect of nitrendipine on end-organ damage in spontaneously hypertensive rats. J Hypertens 2003; 21(10): 1961-7.

48. Zhang C, Chen H, Xie HH, Shu H, Yuan WJ, Su DF. Inflammation is involved in the organ damage induced by sinoaortic denervation in rats. J Hypertens 2003; 21(11): 2141-8.

49.  Wang WZ, Yuan WJ, Su DF. Blockade of N-methyl-D-aspartate receptors within the rostral ventrolateral medulla antagonizes clonidine-induced cardiovascular effects. Auton Neurosci 2003; 109(1-2): 21-8.

50. Cai GJ, Li L, Xie HH, Xu JJ, Miao CY, Su DF. Morphological evidence of reinnervation of the baroreceptive regions in sinoaortic-denervated rats. Clin Exp Pharmacol Physiol 2003; 30(12): 925-9.

2004

51.  Yi-Ming W, Shu H, Miao CY, Shen FM, Jiang YY, Su DF. Asynchronism of the recovery of baroreflex sensitivity, blood pressure, and consciousness from anesthesia in rats. J Cardiovasc Pharmacol 2004; 43(1): 1-7.

52.  Shan ZZ, Dai SM, Fang F, Su DF. Changes of central norepinephrine, beta-endorphin, LEU-enkephalin, peripheral arginine-vasopressin, and angiotensin II levels in acute and chronic phases of sino-aortic denervation in rats. J Cardiovasc Pharmacol 2004; 43(2): 234-41.

53.  Xu LP, Shen FM, Shu H, Miao CY, Jiang YY, Su DF. Synergism of atenolol and amlodipine on lowering and stabilizing blood pressure in spontaneously hypertensive rats. Fundam Clin Pharmacol 2004; 18(1): 33-8.

54.  Su DF, Xu LP, Miao CY, Xie HH, Shen FM, Jiang YY. Two useful methods for evaluating antihypertensive drugs in conscious freely moving rats. Acta Pharmacol Sin 2004; 25(2): 148-51.

55.  Tao X, Zhang SH, Shen FM, Su DF. High-level apoptosis is persistent in myocardiocytes of sinoaortic-denervated rats. J Hypertens 2004; 22(3): 557-63.

56.  Shu H, Yi-Ming W, Xu LP, Miao CY, Su DF. Increased susceptibility of ventricular arrhythmias to aconitine in anaesthetized rats is attributed to the inhibition of baroreflex. Clin Exp Pharmacol Physiol 2004; 31(4): 249-53.

57. Zhang C, Xie HH, Lu ZA, Zhu MJ, Su DF. Inhibition of inflammation contributes to organ protection of atenolol in sinoaortic-denervated rats. J Cardiovasc Pharmacol 2004; 43(5): 663-8.

58.  Miao CY, Xu LP, Liu JG, Xie HH, Yuan WJ, Su DF. Frequent ventricular premature beats increase blood pressure variability in rats. Acta Pharmacol Sin 2004; 25(5): 545-53.

59.  Fu YJ, Shu H, Miao CY, Wang MW, Su DF. Restoration of baroreflex function by ketanserin is not blood pressure dependent in conscious freely moving rats. J Hypertens 2004; 22(6): 1165-72.

60.  Shen FM, Guan YF, Xie HH, Su DF. Arterial baroreflex function determines the survival time in lipopolysaccharide-induced shock in rats. Shock 2004; 21(6): 556-60.

61.  Shen FM, Zhu GM, Miao CY, Guan YF, Su DF. ATP-sensitive potassium channels are involved in adenosine-induced reduction of blood pressure variability in spontaneously hypertensive rats. J Cardiovasc Pharmacol 2004; 44(1): 87-92.

62.  Miao CY, Cai GJ, Tao X, Xie HH, Su DF. Greater hypertrophy in right than left ventricles is associated with pulmonary vasculopathy in sinoaortic-denervated Wistar-Kyoto rats. Clin Exp Pharmacol Physiol 2004; 31(7): 450-5.

63.  Wang WZ, Yuan WJ, Pan YX, Tang CS, Su DF. Interaction between clonidine and N-methyl-D-aspartate receptors in the caudal ventrolateral medulla of rats. Exp Brain Res 2004; 158(2): 259-64.

64.  Wang WZ, Yuan WJ, Tang CS, Su DF. Electrophysiological evidences for the contribution of NMDA receptors to the inhibition of clonidine on the RVLM presympathetic neurons. Brain Res 2004; 1023(1): 163-6.

65.  Li L, Yuan WJ, Su DF. Effects of rat urotensin II on coronary flow and myocardial eNOS protein expression in isolated rat heart. Acta Pharmacol Sin 2004; 25(11): 1444-9.

2005

66.  Xie HH, Miao CY, Jiang YY, Su DF. Synergism of atenolol and nitrendipine on hemodynamic amelioration and organ protection in hypertensive rats. J Hypertens 2005; 23(1): 193-201.

67.  Yang J, Wang WZ, Shen FM, Su DF. Cardiovascular effects of agmatine within the rostral ventrolateral medulla are similar to those of clonidine in anesthetized rats. Exp Brain Res 2005; 160(4): 467-72.

68.  Chen AF, Su DF. A new season of Chinese cardiovascular pharmacology research. Acta Pharmacol Sin 2005; 26(3): 257-8.

69.  Xie HH, Shen FM, Cao YB, Li HL, Su DF. Effects of low-dose ketanserin on blood pressure variability, baroreflex sensitivity and end-organ damage in spontaneously hypertensive rats. Clin Sci (Lond) 2005; 108(6): 547-52.

70.  Wang DS, Xie HH, Shen FM, Cai GJ, Su DF. Blood pressure variability, cardiac baroreflex sensitivity and organ damage in experimentally hypertensive rats. Clin Exp Pharmacol Physiol 2005; 32(7): 545-52.

71.  Su DF, Miao CY. Reduction of blood pressure variability: a new strategy for the treatment of hypertension. Trends Pharmacol Sci 2005; 26(8): 388-90.

72.  Zhan LS, Guan YF, Su DF, Miao CY. Blood pressure variability and baroreflex sensitivity are not different in spontaneously hypertensive rats and stroke-prone spontaneously hypertensive rats. Acta Pharmacol Sin 2005; 26(8): 959-62.

73.  Xie HH, Shen FM, Miao CY, Su DF. Blood pressure, baroreflex sensitivity, and end organ damage in hybrid offspring of spontaneously hypertensive rats and Sprague-Dawley rats. Acta Pharmacol Sin 2005; 26(9): 1049-56.

74.  Cai GJ, Miao CY, Xie HH, Lu LH, Su DF. Arterial baroreflex dysfunction promotes atherosclerosis in rats. Atherosclerosis 2005; 183(1): 41-7.

75.  Shen FM, Xie HH, Lin G, Xu LP, Su DF. Synergistic effects of atenolol and amlodipine for lowering and stabilizing blood pressure in 2K1C renovascular hypertensive rats. Acta Pharmacol Sin 2005; 26(11): 1303-8.

76. Lu LH, Xie HH, Cai GJ, Shen FM, Su DF. Diminished responses to nifedipine imply severe end-organ damage in spontaneously hypertensive rats. J Cardiovasc Pharmacol 2005; 46(6): 836-41.

77.  Xie HH, Chen YY, Miao CY, Shen FM, Su DF. Effects of long-term treatment with candesartan on hemodynamics and organ damage in spontaneously hypertensive rats. Cardiovasc Drugs Ther 2005; 19(6):391-7.

2006

78.  Fu YJ, Wang WZ, Cai GJ, Wang MW, Su DF. Action site of ketanserin enhancing baroreflex function is within the rostral ventrolateral medulla in anesthetized rats. Auton Neurosci 2006; 124(1-2): 31-7.

79.  Sun HW, Miao CY, Liu L, Zhou J, Su DF, Wang YX, Jiang CL. Rapid inhibitory effect of glucocorticoids on airway smooth muscle contractions in guinea pigs. Steroids 2006; 71(2): 154-9.

80.  Shen FM, Zhang SH, Xie HH, Jing Q, Wang DS, Su DF. Early structural changes of aortic wall in sinoaortic-denervated rats. Clin Exp Pharmacol Physiol 2006; 33(4): 358-63.

81.  Wang J, Shen FM, Zhang XF, Wang MW, Su DF. Arterial baroreflex function attenuates depressor effects of antihypertensive drugs in conscious rats. J Pharmacol Sci 2006; 100: 271-7.

82.  Miao CY, Xie HH, Zhan LS, Su DF. Blood pressure variability is more important than blood pressure level in determination of end-organ damage in rats. J Hypertens 2006; 24(6): 1125-35.

83.  Gu XW, Xie HH, Wang J, Shen FM, Su DF. Arterial baroreflex is not involved in salt preference in rats. Clin Exp Pharmacol Physiol 2006; 33(7): 607-11.

84.  Zhang LC, Hu JH, Li L, Gao LH, Zhu QG, Li Z, Wang ZZ, Su DF. In vivo and in vitro evaluation of essential oils from ligusticum chuanxiong hort on the transdermal delivery of flurbiprofen in rabbits. Biol Pharm Bull 2006; 29(6): 1217-22.

85.  Wang J, Shen FM, Wamg MW, Su DF. Effects of nine antihypertensive drugs on blood pressure variability in sinoaortic-denervated rats. Acta Pharmacol Sin 2006; 27(8): 1013-7.

86.  Xie HH, Shen FM, Zhang XF, Jiang YY, Su DF. Blood pressure variability, baroreflex sensitivity and organ damage in spontaneously hypertensive rats treated with various antihypertensive drugs. Eur J Pharmacol 2006; 543(1-3): 77-82.

87.  Su DF. Treatment of hypertension based on measurement of blood pressure variability: lessons from animal studies. Curr Opin Cardiol 2006; 21(5): 486-91.

88.  Zhang XF, Yang RF, Wang J, Zhao L, Li L, Shen FM, Su DF. Arterial baroreflex function does not influence telomere length in kidney of rats. Acta Pharmacol Sin 2006; 27(11): 1409-16.

89.  Han P, Chu ZX, Shen FM, Xie HH, Su DF. Synergism of hydrochlorothiazide and nitrendipine on the reduction of blood pressure and blood pressure variability in spontaneously hypertensive rats. Acta Pharmacol Sin 2006; 27(12): 1575-9.

2007

90.  Li M, Wang J, Xie HH, Shen FM, Su DF. The susceptibility of ventricular arrhythmia to aconitine in conscious Lyon hypertensive rats. Acta Pharmacol Sin 2007; 28(2): 211-5.

91.  Li H, Sun NL, Wang J, Liu AJ, Su DF. Circadian expression of clock genes and angiotensin II type 1 receptors in the suprachiasmatic nucleus of sinoaortic-denervated rats. Acta Pharmacol Sin 2007; 28(4): 484-92.

92.  Guan YF, Chen RH, Wang P, Qin Y, Su DF, Miao CY. Hypertonic and isotonic potassium solutions have different effects on vessel contractility resulting in differences in optimal resting tension in rat aorta. Acta Pharmacol Sin. 2007; 28(5):643-50.

93.  Liu AJ, Ma XJ, Shen FM, Liu JG, Chen H, Su DF. Arterial baroreflex. A novel target for preventing stroke in rat hypertension. Stroke 2007; 38(6): 1916-23.

94.  Shen FM, Wang J, Ni CR, Yu JG, Wang WZ, Su DF. Ketanserin-induced baroreflex enhancement in spontaneously hypertensive rats depends on central 5-HT2A receptors. Clin Exp Pharmacol Physiol 2007; 34(8): 702-7.

95.  Shi KY, Shen FM, Liu AJ, Chu ZX, Cao YL, Su DF. The survival time post-caecal ligation and puncture in sinoaortic denervated rats. J Cardiovasc Pharmacol 2007; 50(2):162-167.

96.  Wang LG, Zeng J, Yuan WJ, Su DF, Wang WZ. Comparative study of NMDA and AMPA/kainate receptors involved in cardiovascular inhibition produced by imidazoline-like drugs in anaesthetized rats. Exp Physiol 2007; 92(5): 849-58.

97.  Lin LL, Liu AJ, Liu JG, Yu XH, Qin LP, Su DF. Protective effects of scutellarin and breviscapine on brain and heart ischemia in rats. J Cardiovasc Pharmacol 2007; 50(3): 327-32.

98.  Ma XJ, Shen FM, Liu AJ, Shi KY, Wu YL, Su DF. Clonidine, moxonidine, folic acid and mecobalamine improve baroreflex function in stroke-prone spontaneously hypertensive rats. Acta Pharmacol Sin 2007; 28(10): 1150-8.

99.  Xie HH, Shen FM, Xu LP, Han P, Miao CY, Su DF. Reduction of blood pressure variability by combination therapy in spontaneously hypertensive rats. J Hypertens 2007; 25(11): 2334-2344.

100.  Ling G, Liu AJ, Shen FM, Cai GJ, Liu JG, Su DF. Effects of combination therapy with atenolol and amlodipine on blood pressure control and stroke prevention in stroke-prone spontaneously hypertensive rats. Acta Pharmacol Sin 2007; 28(11): 1755-60.

101.  Yu XH, Cai GJ, Liu AJ, Chu ZX, Su DF. A novel animal model for motion sickness and its first application in rodents. Physiol Behav 2007; 92(4): 702-7.

2008

102.  Zhang W, Liu AJ, Yiming W, Liu JG, Shen FM, Su DF. Pressor and non-pressor effects of sodium loading on stroke in stroke-prone spontaneously hypertensive rats. Clin Exp Pharmacol Physiol 2008; 35(1): 83-8.

103.  Tao X, Zhang YJ, Shen FM, Guan YF, Su DF. Fosinopril prevents the pulmonary arterial remodeling in sinoaortic-denervated rats by regulating phosphodiesterase. J Cardiovasc Pharmacol 2008; 51(1): 24-31.

104.  Yang RF, Liu AJ, Ma XJ, Li L, Su DF, Liu JG. Sodium Tanshinone IIA sulfonate protects cardiomyocytes against oxidative stress-mediated apoptosis through inhibiting JNK activation. J Cardiovasc Pharmacol 2008; 51(4):396-401.

105.  Xie HH, Zhang XF, Chen YY, Shen FM, Su DF. Synergism of hydrochlorothiazide and nifedipine on blood pressure variability reduction and organ protection in spontaneously hypertensive rats. Hypertens Res 2008; 31(4): 685-91.

106.  Liu AJ, Ling G, Wu J, Shen FM, Wang DS, Lin LL, Liu JG, Su DF. Arterial baroreflex function is an important determinant on the acute cerebral ischemia in rats with middle cerebral artery occlusion. Life Sci, 2008; 83(11-12): 388-93.

107.  Yu JG, Wu J, Shen FM, Cai GJ, Liu JG, Su DF. Arterial baroreflex dysfunction fails to mimic Parkinson’s disease in rats. J Pharmacol Sci 2008; 108(1): 56-62.

108.  Li L, Yi-Ming W, Li ZZ, Zhao L, Yu YS, Li DJ, Xia CY, Liu JG, Su DF. Local RAS and inflammatory factors are involved in cardiovascular hypertrophy in spontaneously hypertensive rats. Pharmacol Res 2008; 58(3-4): 196-201.

2009

109.  Li L, Zhao L, Yi-Ming W, Yu YS, Xia CY, Duan JL, Su DF. Sirt1 hyperexpression in SHR heart related to left ventricular hypertrophy. Can J Physiol Pharmacol. 2009; 87(1): 56-62.

110.  Liu C, Shen FM, Le YY, Kong Y, Liu X, Cai GJ, Chen AF, Su DF. Antishock effect of anisodamine involves a novel pathway for activating α7 nicotinic acetylcholine receptor. Crit Care Med 2009; 37(2): 634-41 (√).

111.  Wang P, Xu TY, Guan YF, Su DF, Fan GR, Miao CY. Perivascular adipose tissue-derived visfatin is a vascular smooth muscle cell growth factor: role of nicotinamide mononucleotide. Cardiovasc Res 2009; 81(2): 370-80.

112.  Wu MY, Ma XJ, Yang C, Tao X, Liu AJ, Su DF, Liu JG. Effects of allisartan, a new AT(1) receptor blocker, on blood pressure and end organ damage in hypertensive animals. Acta Pharmacol Sin. 2009; 30(3): 307-13.

113.  Han P, Shen FM, Xie HH, Chen YY, Miao CY, Mehta JL, Sassard J, Su DF. The combination of atenolol and amlodipine is better than their monotherapy in preventing end organ damage in different types of hypertension in rats. J Cell Mol Med 2009; 13(4): 726-34.

114.  Li DJ, Tang Q, Shen FM, Su DF, Duan JL, Xi T. Over-expressed α7 nicotinic acetylcholine receptor inhibited proinflammatory cytokine release in NIH3T3 cells. J Biosci Bioeng. 2009; 108(2): 85-91.

115.  Qian J, Liu AJ, Zhang W, Wen ZP, Lin LL, Wang JH, Su DF, Liu JG. Protective effects of betaglucin on the myocardial tissue during myocardial infarction in rats and dogs. Acta Pharmacol Sin. 2009; 30(8): 1092-8.

116.  Peng J, Wang YK, Wang LG, Yuan WJ, Su DF, Ni X, Deng XM, Wang WZ. Sympathoinhibitory mechanism of moxonidine: role of the inducible nitric oxide synthase in the rostral ventrolateral medulla. Cardiovas Res 2009; 84(2): 283-91.

117.  Lu GC, Cheng JW, Zhu KM, Ma XJ, Shen FM, Su DF.  A systematic review of angiotensin receptor blockers in preventing stroke. Stroke, 2009; 40: 3876-8.

118.  Wang JL, Wang L, Wu ZT, Yuan WJ, Su DF, Ni X, Yan JJ, Wang WZ. Low dose of moxonidine within the rostral ventrolateral medulla improves the baroreflex sensitivity control of sympathetic activity in hypertensive rat. Acta Pharmacol Sin. 2009; 30(12): 1594-600.

2010

119.  Liu AJ, Guo JM, Xia WL, Su DF. New strategies for the prevention of stroke. Clin Exp Pharmacol Physiol 2010; 37(2): 265-71.

120.  Ying W, Su DF. Frontier in Research Series: Stroke. Introduction. Clin Exp Pharmacol Physiol 2010; 37(2): 236-7.

121.  Su DF. Defining pharmacology of natural products in the 21st century – challenge on multiple fronts. Front Pharmacol 2010, 1: 5. doi: 10.3389/fphar.2010.00005.

122.  Song SW, Liu AJ, Bai C, Su BL, Ma XJ, Shen FM, Duan JL, Su DF. Blood pressure reduction combining baroreflex restoration for stroke prevention in hypertension in rats. Front Pharmacol 2010, 1: 6. doi: 10.3389/fphar.2010.00006.

123.  Ma XJ, Lu GC, Song SW, Liu W, Wen ZP, Zheng X, Lv QZ, Su DF. The features of reserpine-induced gastric mucosal lesions. Acta Pharmacol Sin 2010; 31(8): 938-43.

124.  Xu C, Wang F, Wang B, Li X, Li C, Wang D, Xiong X, Wang P, Lu Q, Wang X, Yang Q, Yin D, Huang Y, Ji L, Wang N, Chen S, Cheng X, Liao Y, Ma X, Su D, Chen G, Xia H, Shi L, Tu X, Wang QK. Minor allele C of chromosome 1p32 single nucleotide polymorphism rs11206510 confers risk of ischemic stroke in the Chinese Han population. Stroke 2010; 41(8): 1587-92.

125.  Wang P, Du H, Zhang RY, Guan YF, Xu TY, Xu QY, Su DF, Miao CY. Circulating and local visfatin/Nampt/PBEF levels in spontaneously hypertensive rats, stroke-prone spontaneously hypertensive rats and Wistar-Kyoto rats. J Physiol Sci. 2010; 60(5): 317-24.

126.  Wang P, Bai C, Xu QY, Xu TY, Su DF, Sassard J, Miao CY. Visfatin is associated with lipid metabolic abnormality in Lyon hypertensive rats. Clin Exp Pharmacol Physiol 2010; 37(9): 894-899.

127.  Du CS, Yang RF, Song SW, Wang YP, Kang JH, Zhang R, Su DF, Xie X. Magnesium lithospermate B protects cardiomyocytes from ischemic injury via inhibition of TAB1-p38 apoptosis signaling. Front Pharmacol 2010 doi:10.3389/fphar.2010.00111.

128.  Guo JM, Liu AJ, Su DF. Genetics of stroke. Acta Pharmacol Sin 2010; 31: 1055-64.

129.  Yu YS, Xie HH, Li L, Song SW, Han P, Cai GJ, Su DF. Effects of low-dose ketanserin on atherosclerosis in rats and rabbits. Can J Physiol Pharmacol 2010; 88(11):1054-60.

130.  Xie HH, Zhou S, Chen D, Channon KM, Su DF, Chen AF. GTP cyclohydrolase I/BH4 pathway protects EPCs via suppressing oxidative stress and thrombospondin-1 in salt-sensitive hypertension. Hypertension 2010; 56(6): 1137-44.

131.  Evans R, Su DF. A new era for Clinical and Experimental Pharmacology and Physiology. Clin Exp Pharmacol Physiol 2010; 37(12): 1105-6.

132.  A potential role of alpha-7 nicotinic acetylcholine receptor in cardiac angiogenesis in a pressure-overload rat model. J Pharmacol Sci 2010; 114: 311-9.

2011

133.  Li DJ, Evans R, Yang ZW, Song SW, Wang P, Ma XJ, Liu C, Xi T, Su DF, Shen FM. Dysfunction of cholinergic anti-inflammatory pathway in hypertensive rats. Hypertension 2011; 57(2): 298-307.

134.  Shen FM, Li DJ, Xie HH, Wang DS, Guan YF, Miao CY, Su DF. Disparity of vascular KATP channels determines the increased blood pressure variability after sinoaortic denervation. Acta Pharmacol Sin 2010; (in press).

135.  Wang P, Xu TY, Guan YF, Tian WW, Viollet B, Rui YC, Zhai QW, Su DF, Miao CY. Nampt protects against ischemic stroke through SIRT1-dependent AMPK pathway. Ann Neurol 2010 (in press).

136.  Liu W, Wang W, Song SW, Gu XF, Ma XJ, Su FY, Liu AJ, Su DF. Synergism of telmisartan and amlodipine on blood pressure reduction and cardio-renal protection in hypertensive rats. J Cardiovasc Pharmacol 2010; (in press).

137.  Peng JF, Wu ZT, Wang YK, Yuan WJ, Ni X, Su DF, Wang W, Xu MJ, Wang WZ. GABAergic mechanism in the rostral ventrolateral medulla contributes to the hypotension of moxonidine. Cardiovasc Res 2010 (in press).

138.  Wang P, Yang FJ, Du H, Guan YF, Xu TY, Xu XW, Su D, Miao CY. Involvement of leptin receptor (LepRb)-STAT3 signaling pathway in brain FTO dawnregulation during energy restriction. Mol Med, 2011 (in press).